WEST LAFAYETTE, Ind., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that Robert Leasure Jr., President and Chief Executive Officer, and Beth Taylor, Chief Financial Officer, will participate in multiple upcoming investor conferences throughout November 2023.
Event: Jefferies London Healthcare Conference
Location: London, United Kingdom
Presentation Date: November 15, 2023
Time: 4:00 PM Greenwich Mean Time
Event: 14th Annual Craig-Hallum Alpha Select Conference
Location: New York, NY
Date: November 16, 2023
Event: 6th Annual Evercore ISI HealthCONx Conference
Location: Miami, FL
Presentation Date: November 29, 2023
Time: 3:00 PM Eastern Time
Link to Webcast
The webcast presentations will be available for viewing and replay under the “Investor Relations” tab of the Company's website at www.inotivco.com.
About Inotiv
Inotiv, Inc. is a leading contract research organization dedicated to providing nonclinical and analytical drug discovery and development services and research models and related products and services. The Company’s products and services focus on bringing new drugs and medical devices through the discovery and preclinical phases of development, all while increasing efficiency, improving data, and reducing the cost of taking new drugs to market. Inotiv is committed to supporting discovery and development objectives as well as helping researchers realize the full potential of their critical R&D projects, all while working together to build a healthier and safer world. Further information about Inotiv can be found here: https://www.inotivco.com/.
| Company Contact | Investor Relations |
| Inotiv, Inc. | LifeSci Advisors |
| Beth A. Taylor, Chief Financial Officer | Bob Yedid |
| (765) 497-8381 | (516) 428-8577 |
| This email address is being protected from spambots. You need JavaScript enabled to view it. | This email address is being protected from spambots. You need JavaScript enabled to view it. |
| Last Trade: | US$3.94 |
| Daily Change: | -0.14 -3.43 |
| Daily Volume: | 1,343,326 |
| Market Cap: | US$102.520M |
December 17, 2024 December 03, 2024 August 08, 2024 May 15, 2024 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
